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	 Topical	 microbicides	 such	 as	 Nonoxynol‐9	 (N9)	 and	 KY	 jelly	 have	 been	 used	 as	 vaginal
microbicides	 in	 clinical	 trials	 as	 anti‐HIV‐1	 products.	 The	 objective	 of	 this	 study	 was	 to
determine	 if	 the	 use	 of	 these	 microbicides	 may	 cause	 production	 of	 proinflammatory
cytokines	in	vitro.	Such	cytokines	include,	tumor	necrosis	factor‐α	(TNF‐α),	interlukin‐1β	(IL‐
1β),	 interlukin‐6	 (IL‐6),	 and	 Interlukin‐8	 (IL‐8).	 Cellular	 viability	 was	 determined	 for	 the
peripheral	blood	mononuclear	cells	(PBMCs)	and	Macrophages	by	culturing	them	for	24	hours
in	 the	presence	of	serial	dilutions	of	product	or	placebo.	Product	and	placebo	dilutions	 that
gave	culture	viabilities	of	≥	60%	compared	to	control	cultures	were	considered	to	be	nontoxic.
The	non‐toxic	dilutions	were	1:100	for	KY	jelly	in	both	PBMCs	and	Macrophages.	Whereas,	the
non‐toxic	dilutions	were	1:1000	for	N9	in	both	PBMCs	and	Macrophages.	The	values	of	IL1β,
TNF‐α,	were	 0.1	 <	 2.0	 pg/mL	 for	 both	 PBMCs	 and	macrophages.	 The	 levels	 of	 IL‐8	 ranged
between	9‐13	pg/mL	and	12‐16	pg/mL	for	PBMCs	and	macrophages,	respectively.	The	levels
of	 IL‐6	 were	 0.11	 g/mL	 and	 0.019	 pg/mL	 for	 PBMCs	 and	 macrophages,	 respectively.	 The
results	were	not	statistically	significant	in	difference	for	IL‐1β,	IL‐6,	and	IL‐8	(p	>	0.001)	when
N9	was	compared	to	KY	jelly.	However,	the	results	were	significant	when	comparing	N9	to	KY
jelly	 for	 TNF‐α	 (p	 <	 0.001)	 production.	 The	 two	 microbicides	 tested	 in	 their	 non‐toxic
formulation	in	the	two	models	of	PBMCs	and	macrophages	showed	relatively	low	levels	of	IL‐
1b,	 TNF‐α	 and	 IL‐6.	 This	 indicated	 safety	 and	 low	 toxicity	 of	 these	microbicide	 in	 terms	 of
cytokines	release.	On	the	other	hand,	IL‐8	has	shown	relatively	higher	levels	in	all	microbicide
tested	in	their	non‐toxic	formulation.	
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1.	Introduction	
	
The	 HIV	 epidemic	 continues	 throughout	 the	world	 and	 is	
accelerating	in	many	areas	despite	almost	30	years	of	research	
and	 prevention	 efforts.	 Approximately	 34	 million	 people	
worldwide	 are	 carriers	 of	 HIV	 in	 2009	 with	 95%	 of	 these	
people	 living	 in	 developing	 countries;	 in	 particular,	 many	
African	 countries	 have	 HIV	 prevalence	 as	 high	 as	 36%.	 The	
majority	 of	 all	 adult	 HIV‐1	 transmissions	 occur	 through	
heterosexual	 intercourse	 [1].	 This	 indicates	 that	 additional	
prevention	methods	are	needed	 in	combination	with	 the	 risk‐
reduction	 counseling	 programs	 and	 condom	 promotion	
methods,	which	already	exist.	Therefore,	the	identification	of	an	
affordable	 vaginal	 microbicide	 that	 is	 safe	 and	 decreases	 the	
risk	of	HIV	transmission	is	extremely	important	and	should	be	
considered	a	high	priority.	
Currently,	 there	 is	 no	 commercially	 available	 vaginal	
microbicide	 with	 proven	 anti‐HIV	 efficacy.	 However,	 it	 is	 a	
pivotal	 time	 in	 HIV	 microbicide	 research,	 in	 which	 more	
resources	 are	becoming	 available	 and	progress	 is	 being	made	
in	 the	 field.	 For	 example,	 the	 well‐known	 spermicide	
Nonoxynol‐9	 (N9)	 had	 been	 shown	 to	 inactivate	 HIV	 [2]	 and	
thus	 became	 popular	 for	 use	 in	 safe‐sex	 practices.	 Recent	
studies,	 however,	 have	 shown	 that	 N‐9	 actually	 increases	 the	
risk	 of	 HIV‐1	 transmission,	 possibly	 due	 to	 increased	 HIV	
shedding	 and	 increased	 recruitment	 of	 CD4+	 target	 cells	
associated	 with	 N‐9	 induced	 vaginal	 inflammation	 [3].	 This	
finding	may	be	responsible	for	the	combination	of	N‐9	with	KY	
jelly	as	a	modified	vaginal	lubricant.	Although	microbicides	are	
not	 yet	 being	 distributed	 and	 sold,	 several	 microbicide	
candidates	 are	 actively	 being	 tested	 for	 anti‐HIV	 activity	 in	
phase	I	and	phase	II	clinical	trials	[4].	
Over	 the	 counter	 (OTC)	 vaginal	 lubricants	 that	 fall	 under	
the	safest	category	of	the	Food	and	Drug	Administration	(FDA)	
are	also	worthy	for	study	because	they	do	not	cause	 irritation	
upon	 repeated	 use,	 readily	 available,	 inexpensive,	 widely	
accepted	by	the	public,	and	would	provide	women	with	choice	
if	 their	 male	 partners	 do	 not	 choose	 to	 wear	 condoms	 [5].	
Examples	of	OTC	lubricants	include	Astroglide	and	KY	Jelly.	
The	 ideal	 microbicide	 or	 lubricant	 should	 block	 HIV	
infection	 without	 inducing	 mucosal	 irritation	 in	 the	 genital	
tract.	 It	 should	also	have	 low	toxicity	 for	cells	and	the	natural	
microbial	flora	in	the	female	genital	tract.	Additionally,	it	must	
be	affordable	and	readily	available	to	be	distributed.	Therefore	
any	topical	microbicide	approved	for	human	use	will	need	to	be	
first	evaluated	for	epithelial	toxicity	and	primary	immune	cells,	
because	the	product	will	come	in	direct	contact	with	vaginal	or	
rectal	mucosal	surfaces.		
Important	to	the	study	of	microbicides	is	an	understanding	
of	 the	biology	of	 sexual	 transmission.	 It	was	 initially	 reported	
that	cell‐free	HIV	in	seminal	fluid	was	the	major	source	of	male‐
to‐female	 transmission,	 but	 recent	 studies	 suggest	 that	 virus‐
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infected	 leukocytes	 (CD4+	 mononuclear	 cells)	 in	 semen	 may	
also	cause	infections	[6‐12].	In	addition,	it	has	been	found	that	
most	 of	 the	 infectious	 virus	 in	 body	 fluids	 and	 secretions	 are	
cell‐associated	 [13‐16].	 These	 infected	 leukocytes	 have	 the	
potential	 of	 directly	 infecting	 mucosal	 epithelial	 cells	 or	
penetrating	 the	 epithelial	 layer	 [6‐11].	 In	 contrast,	 genital	
mucosa	 exposed	 to	 cell‐free	 virus	 has	 very	 low	 infectivity	 for	
epithelial	cells	lacking	the	CD4	receptor.	Therefore,	 leukocytes	
may	play	a	role	in	sexual	transmission	of	HIV	and	they	must	be	
considered	in	the	development	of	an	effective	microbicide	[17].	
The	objectives	of	this	study	were:		
‐	 To	 determine	 whether	 OTC	 lubricants	 and	 candidate	
microbicides	 (N9‐KY)	 are	 cytotoxic	 to	 a	major	 target	 for	 HIV	
infection,	 peripheral	 blood	 mononuclear	 cells	 (PBMCs),	
macrophages,	 and	 epithelial	 Caco2	 cells.	 Cytotoxicity	 was	
assessed	 using	 cell	 TiterGlo	 assay	 measuring	 the	 levels	 of	
cellular	ATP	production.		
‐	To	determine	if	topical	microbicides	could	induce	genital	
tract	 inflammation	 and	 thus	 increase	 the	 likelihood	 of	 HIV	
transmission	by	measuring	the	 levels	of	 tumor	necrosis	 factor	
(TNF‐α),	 interleukin‐1β,	 interleukin‐6,	 and	 interleukin‐8	 in	
PBMCs	and	macrophage	cell	cultures	after	exposure	 to	 topical	
microbicides.	
	
2.	Experimental	
	
Epithelial	cell	lines	were	obtained	from	the	American	Type	
Culture	 Collection	 (Manassas,	 VA).	 Urogenital	 epithelial	 cell	
lines,	ME‐180	 [18]	 and	HEC‐1‐A	 [19],	were	 grown	 in	McCoy’s	
5A	 supplemented	 with	 10%	 fetal	 bovine	 serum,	 100	 g/mL	
streptomycin,	 100	 U/ml	 penicillin,	 and	 100	 mM	 L‐glutamine.	
Colorectal	 epithelial	 cell	 lines,	 Caco‐2	 [20],	 were	 grown	 in	
DMEM	(C‐DMEM)	supplemented	with	10%	fetal	bovine	serum,	
0.1	mM	nonessential	amino	acids,	1	mM	sodium	pyruvate,	100	
g/mL	 streptomycin,	 100	 U/mL	 penicillin,	 and	 100	 mM	 L‐
glutamine.	 The	 epithelial	 cell	 lines	were	maintained	 at	 37	 oC,	
7%	CO2.		
Normal	 human	 PBMCs	 were	 obtained	 by	 leukophoresis	
from	 HIV‐1‐negative	 blood	 donors,	 purified	 by	 differential	
centrifugation,	 and	 stored	 in	 the	 gas	 phase	 of	 liquid	 nitrogen	
until	 needed.	 PBMCs	 were	 CD8‐depleted	 using	 anti‐CD8‐
conjugated	magnetic	beads	(Dynal,	Lake	Success,	NY)	according	
to	 the	 manufacturer’s	 instructions.	 The	 CD8‐depleted	 PBMCs	
were	 stimulated	 for	 3	 days	 at	 37	 oC,	 7%	 CO2	 in	 C‐RPMI	
supplemented	 with	 10%	 IL‐2	 and	 0.5	 or	 1.0	 µg/mL	
phytohemagglutinin‐P.	 After	 3	 days,	 the	 PBMCs	were	washed	
and	 suspended	 in	 C‐RPMI	 with	 10%	 IL‐2.	 Human	monocytes	
(Advanced	Biotechnologies,	 Inc.,	 Columbia,	MD)	were	 allowed	
to	differentiate	to	Macrophages	and	were	maintained	in	DMEM	
supplemented	with	20%	heat‐inactivated	fetal	calf	serum,	10%	
human	 AB	 serum,	 100	 μg/mL	 streptomycin,	 100	 U/mL	
penicillin,	 and	 100	 mM	 L‐glutamine	 at	 37	 oC,	 7%	 CO2.	
Macrophages	were	maintained	 in	 the	 same	media	and	culture	
conditions.	
K‐Y®	 plus	 nonoxynol‐9	 (KY‐N9;	 Ortho‐McNeil	
Pharmaceuticals,	Inc.,	Raritan,	NJ)	and	K‐Y®	Jelly	(McNeil‐PPC,	
Inc.,	 Skillman,	 NJ)	 are	 approved	 over‐the‐counter	 (OTC)	
products.	
	
2.1.	Methods	
	
2.1.1.	Epithelial	Caco2	cells	
	
Fifty	thousand	cells	were	added	per	well	in	a	96‐well	plate.	
After	an	overnight	incubation	to	allow	the	cells	to	adhere	to	the	
well,	dilutions	of	the	products	or	their	placebos	were	added	to	
the	 wells	 in	 triplicate	 for	 either	 24	 or	 2	 hours	 per	 day	 for	 5	
days.	 For	 the	 5	 day	 exposure,	 the	 products	 or	 placebos	were	
diluted	in	the	appropriate	epithelial	cell	medium	and	added	to	
the	culture	for	2	hours	and	then	washed	twice	with	phosphate‐
buffered	saline.	Fresh	medium	was	reapplied.	Wells	containing	
cells	alone	were	assayed	in	triplicate	and	served	as	controls.	To	
determine	 culture	 viability,	 cellular	 ATP	 concentrations	 were	
measured	 using	 the	 CellTiter‐GloTM	 assay	 (Promega	 Corp.,	
Madison,	 WI)	 according	 to	 the	 manufacturer’s	 instructions.	
Culture	 ATP‐dependent	 luminescence	 was	 measured	 on	 a	
DYNEX	MLX	instrument	(Franklin,	MA)	and	reported	as	relative	
light	 units	 (RLU).	 The	 RLU	 ratio	 of	 test	 cultures	 and	 control	
cultures	was	used	to	assess	cellular	viability.	
	
2.1.2.	Primary	Immune	Cells	“PBMCs	and	Macrophages”	
	
Activated	 PBMCs	 were	 mixed	 with	 serial	 dilutions	 of	
product	or	placebo	in	medium	or	medium	alone	(control),	and	
1×106	 cells	 were	 placed	 in	 a	 24	 well	 plate.	 Test	 and	 control	
cultures	were	set‐up	in	triplicate.	After	24	hours,	cultures	were	
gently	mixed	and	100	µL	was	removed	for	testing.	Cell	viability	
was	 determined	 as	 described	 above.	 Macrophages	 were	
incubated	 with	 serial	 dilutions	 of	 a	 product	 or	 placebo	 in	
medium	or	medium	alone	 (control)	 and	 cultured	 in	 a	24	well	
plate.	Test	and	control	cultures	were	set‐up	in	duplicate.	After	
24	 hours,	 media	 or	 product	 dilutions	 were	 removed	 and	 the	
wells	were	washed	twice	with	fresh	medium	before	500	µL	of	
reconstituted	 CellTiter‐GloTM	 reagent	was	 added	 to	 each	well.	
The	 plate	 was	 placed	 on	 a	 horizontal	 rocker	 for	 30	 minutes.	
Viability	was	determined	as	described	above.	
	
2.1.3.	In‐vitro	Inflammation	induction	studies	
	
PBMCs	 or	 Macrophages	 (1×106/well)	 were	 incubated	 in	
medium	 containing	 (1.0	 mL	 media/well)	 and	 a	 nontoxic	
concentration	 of	 product	 or	 placebo	 or	media	 alone	 (control)	
for	4	hours.	The	PBMCs	were	then	cultured	in	medium	alone	at	
1×106	 cells/mL/well	 in	 a	 24	 well	 plate	 for	 4	 hours.	 Each	
product,	 placebo,	 and	 control	 was	 tested	 in	 triplicate.	 The	
product	and	placebo	were	exposed	to	cells	in	their	non‐toxic	as	
well	as	toxic	forms	(Table	1).	Culture	supernatants	were	stored	
at	 ‐80	 oC	 until	 they	 were	 assayed	 for	 proinflammatory	
cytokines	 using	 Human	 QuantikinesR	 HS	 cytokines	
immunoassay	 kit	 (R	 &	 D	 systems,	 Minneapolis,	 MN).	 The	
epithelial	cell	lines	and	the	primary	immune	cells	were	cultured	
with	 dilutions	 of	 products	 or	 placebo	 for	 24	 hours.	 After	
washing,	 culture	 viability	 was	 determined	 using	 Cell	 Titer‐
GloTM	 assay	 to	 the	manufacturere’s	 instructions.	 The	 dilutions	
of	 the	 products	 or	 placebo	 that	 resulted	 in	 ≥60%	 culture	
viability	were	presented.	
	
Table	 1.	 Nontoxic	 dilutions	 of	 the	 candidate	 microbicide	 and	 placebo	
formulations	in	epithelial	cell	lines	and	primary	immune	cells1.	
Products	 Epithelial	Cell	
Lines‐Caco2	
Primary	immune	
Cells‐PMBCs	
Primary	Immune	
Cells‐MΦ	
KY‐N9	 1:1000	 1:1000	 1:1000	
KY	jelly	 1:100	 1:100	 1:100	
	
	
3.	Results	and	discussion		
	
The	 KY	 and	 N9	 formulations	 were	 much	more	 toxic,	 and	
when	 tested	 at	 their	 nontoxic	 concentrations	 against	 primary	
immune	 cells	 PBMCs	 and	 Macrophages	 and	 epithelial	 cells.	
Originally	developed	as	a	spermicide,	initial	reports	showed	N9	
had	 in	 vitro	 activity	 against	 sexually	 transmitted	 diseases	
including	HIV‐1	[21,22].	Despite	this	promising	early	work,	one	
study	 reported	 that	 the	 N9	 antiviral	 activity	 only	 occurred	 at	
doses	 that	 were	 cytotoxic	 [23].	 Several	 clinical	 studies	 have	
reported	 epithelial	 disruption	 and	 inflammation	of	 the	 female	
genital	tract	[24,25]	and	two	additional	studies	showed	toxicity	
of	 the	 rectal	 mucosa	 in	 humans	 and	 nonhuman	 primates	
[26,27].	 Since	 that	 time,	 the	 recommendation	 has	 been	 that	
products	 containing	 N9	 not	 be	 used	 for	 HIV‐1	 prevention,	
especially	rectally.	Our	data	were	consistent	with	these	results	
showing	that	KY‐N9	was	highly	toxic	to	the	cells	tested	and	had	
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reduced	 efficacy	 in	 blocking	 HIV‐1	 infection	 at	 its	 nontoxic	
concentration.		
Inflammation	 of	 the	 female	 reproductive	 tract	 increases	
susceptibility	 to	 HIV	 and	 other	 viral	 infections	 and,	 thus,	 it	
becomes	 a	 serious	 liability	 for	 vaginal	 products.	 Excessive	
release	 of	 proinflammatory	 cytokines	 may	 alter	 the	 mucosal	
balance	 between	 tissue	 destruction	 and	 repair	 and	 linked	 to	
enhanced	penetration	and	replication	of	viral	pathogens	upon	
chemical	insult.	
We	have	placed	the	emphasis	on	value	of	interleukin	(IL‐)‐
1β,	TNF‐α,	IL‐6	and	IL‐8	as	marker	of	mucosal	toxicity	because	
they	 represent	 three	 families	of	 cytokines	with	different	 roles	
in	 inflammatory	tissue	damage	and	HIV‐1	pathogenesis.	IL‐1β,	
TNF‐α,	 and	 IL‐6	 induce	HIV‐1	 expression	 via	NF‐κB	mediated	
HIV‐1	long	terminal	repeat	(LTR)	activation,	while	IL‐8	triggers	
the	recruitment	of	HIV‐1	susceptible	cells	 to	 the	 inflammation	
site	 and	 may	 also	 stimulate	 HIV‐1	 replication	 in	 T	 cells	 and	
macrophages	 [28].	 All	 of	 these	 three	 cytokines	 are	 expressed	
constitutively	at	low	levels	by	cervico	vaginal	keratinocytes	and	
are	 significantly	 induced	 via	 NF‐κB	 mediated	 signal	
transduction	 pathways	 by	 proinflammatory	 stimuli	 and	
common	sexually	transmitted	pathogens	[28].	
In	this	study,	we	have	investigated	the	correlation	between	
the	 response	 of	 peripheral	 blood	mononuclear	 cells	 (PBMCs)	
and	 macrophages	 from	 non‐infected	 cells	 (Figure	 1‐4).	 As	 a	
result,	 PBMCs	 and	 macrophages	 were	 exposed	 to	 non‐toxic	
according	 to	 microbicides	 dilutions.	 Higher	 concentrations	
proinflammatory	 cytokines	 in	 genital	 secretions	 have	 been	
associated	with	higher	levels	of	vaginal	virus	in	HIV‐1	infected	
women.	 Therefore,	 it	 will	 be	 important	 to	 know	 if	 non‐toxic	
levels	 of	 the	 microbicides	 increase	 production	 of	 these	
cytokines	[29].	
	
	
	
Figure	 1.	 The	 ability	 of	 topical	 microbicide	 formulation	 to	 induce	
proinflammatory	 cytokine	 TNF‐α	 in	 peripheral	mononuclear	 cells	 (PBMCS)	
and	macrophages.	PBMCS	and	macrophages	were	suspended	in	1	mL	media	
mixed	with	 non‐toxic	 formulations	 of	microbicides	 for	 4	 hrs.	 The	 products	
were	 tested	 in	 triplicate.	 Post	 exposure	 to	 microbicides,	 the	 supernatant	
were	 collected	and	assayed	 for	 cytokine‐TNF‐α	release	using	ELISA	 (R	&	D	
systems).	The	data	presented	are	average	±	standard	deviation	of	the	means.	
	
Currently,	 there	 is	 no	 commercially	 available	 microbicide	
with	 anti‐HIV	 activity.	 However,	 it	 is	 a	 pivotal	 time	 in	 HIV	
microbicide	 research,	 in	which	more	 resources	 are	 becoming	
available	and	progress	is	being	made	in	the	field.	For	example,	
the	well‐known	spermicidal	Nonoxynol‐9	(N9)	had	been	shown	
to	inactivate	HIV‐1	[2]	and	thus	became	popular	for	use	in	safe‐
sex	 practices.	 Recent	 studies,	 however,	 have	 shown	 that	 N‐9	
actually	 increases	 the	 risk	 of	 HIV‐1	 transmission	 [3],	 due	 to	
increased	 HIV‐1	 shedding	 and	 increase	 recruitment	 of	 CD+4	
target	 cells	 associated	with	 vaginal	 inflammation.	 In	 addition,	
N‐9	 use	 promotes	 HIV‐1	 transmission	 through	 interleukin‐
mediated	 NF‐κB	 activation,	 and	 increased	 replication	 [30].	 In	
this	 study,	 N‐9	 showed	 levels	 of	 TNF‐α,	 IL‐1β	 and	 IL‐6	
cytokines	were	<	2	pg/mL,	whereas	elevated	 level	 of	 IL‐8	has	
been	observed	in	our	in	vitro	study.	In	one	study,	showed	that	
N‐9	induced	IL‐α/β	release,	activation	if	NF‐κB	and	subsequent	
IL‐8	 up‐regulation	 by	 cervical	 and	 vaginal	 epithelial	 in	 vitro	
[32].	 Also	 in	 one	 study	 shows	 the	 effects	 of	 formulations	
containing	 the	 common	 spermicide	 active	 ingredient,	
nonoxynol‐9	(N9),	on	epithelial	tissue	containing	epithelial	VEC	
cells,	 with	 increasing	 N9	 concentration,	 the	 tissue	 viability	
decreases	 and	 the	 IL‐1β	 release	 increase.	 Such	 assays	 can	 be	
used	 to	predict	 toxicity	of	 vaginal	 care	products,	microbicides	
and	other	chemical	agents.	
	
	
	
Figure	 2.	 The	 ability	 of	 topical	 microbicide	 formulation	 to	 induce	
proinflammatory	 cytokine	 IL‐1β	 in	 peripheral	 mononuclear	 cells	 (PBMCS)	
and	macrophages.	PBMCS	and	macrophages	were	suspended	in	1	mL	media	
mixed	with	 non‐toxic	 formulations	 of	microbicides	 for	 4	 hrs.	 The	 products	
were	 tested	 in	 triplicate.	 Post	 exposure	 to	 microbicides,	 the	 supernatant	
were	 collected	 and	 assayed	 for	 cytokine	 IL‐1β	 release	 using	 ELISA	 (R	 &	D	
systems).	The	data	presented	are	average	±	standard	deviation	of	the	means.	
	
	
	
	
Figure	 3.	 The	 ability	 of	 topical	 microbicide	 formulation	 to	 induce	
proinflammatory	cytokine	IL‐8	in	peripheral	mononuclear	cells	(PBMCS)	and	
macrophages.	 PBMCS	 and	 macrophages	 were	 suspended	 in	 1	 mL	 media	
mixed	with	 non‐toxic	 formulations	 of	microbicides	 for	 4	 hrs.	 The	 products	
were	 tested	 in	 triplicate.	 Post	 exposure	 to	 microbicides,	 the	 supernatant	
were	 collected	 and	 assayed	 for	 cytokine	 IL‐8	 release	 using	 ELISA	 (R	 &	 D	
systems).	The	data	presented	are	average	±	standard	deviation	of	the	means.	
	
4.	Conclusion	
	
In	 conclusion	 all	 microbicides	 tested	 in	 their	 non‐toxic	
formulation	 in	 the	 two	 models	 of	 PBMCs	 and	 macrophages	
showed	 relatively	 low	 levels	 of	 IL‐1b,	 TNF‐α	 and	 IL‐6.	 This	
indicated	safety	and	low	toxicity	of	these	microbicide	in	terms	
of	 cytokines	 release.	 Also,	 the	 usage	 of	 these	microbicieds	 as	
anti‐HIV	 formulation	will	 not	 trigger	 cytokine	 release.	 On	 the	
other	 hand,	 IL	 has	 shown	 relatively	 higher	 levels	 in	 all	
microbicide	 tested	 in	 their	 non‐toxic	 formulation.	 This	
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indicated	 that	 microbicide	 induced	 the	 release	 of	 IL‐8	 could	
trigger	the	recruitment	of	HIV‐1	susceptible	cells	and	increase	
HIV‐1	 replication.	 The	 only	 way	 to	 support	 these	 results	 by	
clinical	trials	including	phase‐1	safety	studies.	
	
	
	
Figure	 4.	 The	 ability	 of	 topical	 microbicide	 formulation	 to	 induce	
proinflammatory	cytokine	IL‐6	in	peripheral	mononuclear	cells	(PBMCS)	and	
macrophages.	 PBMCS	 and	 macrophages	 were	 suspended	 in	 1	 mL	 media	
mixed	with	 non‐toxic	 formulations	 of	microbicides	 for	 4	 hrs.	 The	 products	
were	 tested	 in	 triplicate.	 Post	 exposure	 to	 microbicides,	 the	 supernatant	
were	 collected	 and	 assayed	 for	 cytokineIL‐6	 release	 using	 ELISA	 (R	 &	 D	
systems).	The	data	presented	are	average	±	standard	deviation	of	the	means.	
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